Loading
A phase 2 trial of Methoxsalen in Skin cancer and Melanoma, run by Therakos LLC, not yet recruiting.
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure is a phase 2 interventional study registered as NCT07619898 by Therakos LLC, with 112 participants planned, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab, Infliximab, Mycophenolate Mofetil (MMF), Azathioprine. Conditions recorded: Colitis, Hepatitis, Melanoma (Skin Cancer).
Linked to the drug Methoxsalen because the registry names it among its interventions and Skin cancer and Melanoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Methoxsalen (extracorporeal photopheresis) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/